Izalontamab brengitecan for HR+/HER2– breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial. // The Lancet. – URL: https://www.sciencedirect.com/science/article/pii/S0140673626020969?dgcid=rss_sd_all
Izalontamab brengitecan for HR+/HER2– breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial. The Lancet. https://www.sciencedirect.com/science/article/pii/S0140673626020969?dgcid=rss_sd_all
“Izalontamab brengitecan for HR+/HER2– breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.” The Lancet.
@article{article117870,
title = {Izalontamab brengitecan for HR+/HER2– breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial},
journal = {The Lancet},
url = {https://www.sciencedirect.com/science/article/pii/S0140673626020969?dgcid=rss_sd_all}
}
ABSTRACT As leadership education continues to evolve, increasing attention has been given to fostering learners’ leadership identity, capacity, and efficacy. Drawing on collaborative conversations with 12 leadership educators...